Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes

Stryker Corporation (NYSE:SYK) is one of the best healthcare AI stocks to buy now. On December 11, Citi cut the price target on Stryker Corporation (NYSE:SYK) from $455 to $420, while maintaining a Buy rating on the shares. This adjustment, the firm said, is part of a sector-wide adjustment as it formulates its 2026 outlook.

Independently of the analyst action, on December 11, Stryker’s Board of Directors declared a $0.88 per share quarterly dividend, payable on January 30, 2026. This payment is 4.8% higher than the previous figure paid in October 2025. With this payment, the new annualized dividend equates to $3.52 per share.

In another update, on December 4, the company appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026. Stiles will oversee the company’s global businesses, corporate strategy, and mergers and acquisitions activities. He joined Stryker in 1999 and has served as Group President of Orthopaedics and Spine since 2019.

At the same time, Dylan Crotty, another Stryker veteran currently serving as President of Instruments, will be promoted to Group President of Orthopaedics. Crotty will succeed Stiles. He has previously been the head of Trauma and Extremities and European operations, and is noted for operational leadership and collaboration.

Stryker Corporation (NYSE:SYK) designs and manufactures medical technologies across orthopedics, surgical equipment, and neurotechnology. The company applies AI in areas such as surgical robotics, predictive analytics for patient care, enhanced imaging, inventory management, and remote monitoring.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.